文献速递白血病

小分子IODVA1靶向VAV3抑制RAC信号并克服急性淋巴细胞白血病酪氨酸激酶抑制剂耐药

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2021-10-28

该研究利用细胞、小鼠及人源化模型,鉴定小分子IODVA1靶向酪氨酸磷酸化依赖的RacGEF VAV3,从而抑制RAC激活与信号。在BCR-ABL1(T315I) B-ALL及Ph+患者来源异种移植模型中,IODVA1清除白血病增殖活性并优于达沙替尼或帕纳替尼,且停药后反应更持久。儿童白血病样本体外敏感且依赖VAV3。

要点

  • IODVA1通过结合VAV3抑制RAC信号并增加BCR-ABL1转化细胞凋亡。
  • 在TKI耐药BCR-ABL1(T315I) B-ALL中,IODVA1持久降低体内RAC信号并根除白血病增殖活性。
  • 在难治性儿童Ph+和TKI耐药Ph+ B-ALL PDX模型中,IODVA1优于达沙替尼或帕纳替尼且停药后反应更持久。

核心结论

  • IODVA1通过靶向VAV3抑制RAC信号,可克服BCR-ABL1驱动及Ph样急性淋巴细胞白血病的TKI耐药。

研究设计与样本

  • 研究使用RAC依赖的BCR-ABL1驱动和Ph样急性淋巴细胞白血病的细胞、小鼠及人源化模型。

主要发现

  • IODVA1结合VAV3,抑制RAC激活与信号,并增加BCR-ABL1转化细胞的促凋亡活性。
  • Vav3缺失背景的BCR-ABL1白血病细胞和动物模型对IODVA1无反应。
  • IODVA1持久降低体内RAC信号,在停药后根除TKI耐药BCR-ABL1(T315I) B-ALL细胞的白血病增殖活性。
  • 在治疗难治性儿童Ph+和TKI耐药Ph+ B-ALL患者来源异种移植模型中,IODVA1比标准治疗达沙替尼或帕纳替尼更好地抑制白血病负荷,且停药后反应更持久。
  • 具有多种遗传损伤的儿童白血病样本体外对IODVA1高度敏感,且该敏感性依赖VAV3。

临床怎么用

  • IODVA1代表一类靶向RacGEF的新型药物,有望作为抗肿瘤治疗用于TKI耐药的BCR-ABL1阳性或Ph样急性淋巴细胞白血病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant RHO guanine nucleotide exchange factor (RhoGEF) activation is chief mechanism driving abnormal activation of their GTPase targets in transformation and tumorigenesis. Consequently, a small-molecule inhibitor of RhoGEF can make an anti-cancer drug. We used cellular, mouse, and humanized models of RAC-dependent BCR-ABL1-driven and Ph-like acute lymphoblastic leukemia to identify VAV3, a tyrosine phosphorylation-dependent RacGEF, as the target of the small molecule IODVA1. We show that through binding to VAV3, IODVA1 inhibits RAC activation and signaling and increases pro-apoptotic activity in BCR-ABL1-transformed cells. Consistent with this mechanism of action, cellular and animal models of BCR-ABL1-induced leukemia in Vav3-null background do not respond to IODVA1. By durably decreasing in vivo RAC signaling, IODVA1 eradicates leukemic propagating activity of TKI-resistant BCR-ABL1(T315I) B-ALL cells after treatment withdrawal. Importantly, IODVA1 suppresses the leukemic burden in the treatment refractory pediatric Ph+ and TKI-resistant Ph+ B-ALL patient-derived xenograft models better than standard-of-care dasatinib or ponatinib and provides a more durable response after treatment withdrawal. Pediatric leukemia samples with diverse genetic lesions show high sensitivity to IODVA1 ex vivo and this sensitivity is VAV3 dependent. IODVA1 thus spearheads a novel class of drugs that inhibits a RacGEF and holds promise as an anti-tumor therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hegde S, Gasilina A, Wunderlich M, et al. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia. 2021. PMID: 34711926. doi:10.1038/s41375-021-01455-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。